HK1175846A1 - Cytotoxicity mediation of cells evidencing surface expression of cd44 cd44 - Google Patents
Cytotoxicity mediation of cells evidencing surface expression of cd44 cd44Info
- Publication number
- HK1175846A1 HK1175846A1 HK13103290.6A HK13103290A HK1175846A1 HK 1175846 A1 HK1175846 A1 HK 1175846A1 HK 13103290 A HK13103290 A HK 13103290A HK 1175846 A1 HK1175846 A1 HK 1175846A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- surface expression
- mediation
- cytotoxicity
- cytotoxicity mediation
- cells evidencing
- Prior art date
Links
- 230000003013 cytotoxicity Effects 0.000 title abstract 2
- 231100000135 cytotoxicity Toxicity 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000007402 cytotoxic response Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 238000000159 protein binding assay Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/647,818 US7189397B2 (en) | 1999-10-08 | 2003-08-22 | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1175846A1 true HK1175846A1 (en) | 2013-07-12 |
Family
ID=34216605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13103290.6A HK1175846A1 (en) | 2003-08-22 | 2013-03-18 | Cytotoxicity mediation of cells evidencing surface expression of cd44 cd44 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7189397B2 (xx) |
EP (1) | EP1667716B8 (xx) |
JP (2) | JP4981448B2 (xx) |
CN (2) | CN102778562B (xx) |
AT (1) | ATE538811T1 (xx) |
CA (1) | CA2536359A1 (xx) |
ES (1) | ES2379155T3 (xx) |
HK (1) | HK1175846A1 (xx) |
NZ (1) | NZ545477A (xx) |
WO (1) | WO2005018667A1 (xx) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7419792B2 (en) * | 1999-10-08 | 2008-09-02 | Arius Research Inc. | Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody |
US20080124327A1 (en) * | 1999-10-08 | 2008-05-29 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8071072B2 (en) * | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20050100542A1 (en) * | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20090004103A1 (en) * | 1999-10-08 | 2009-01-01 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8048416B2 (en) * | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7947496B2 (en) * | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7252821B2 (en) * | 1999-10-08 | 2007-08-07 | Arius Research Inc. | Cancerous disease modifying antibodies |
US7976852B2 (en) * | 2005-04-26 | 2011-07-12 | Eisai R&D Management Co., Ltd. | Compositions and methods for cancer immunotherapy |
WO2007133725A1 (en) * | 2006-05-12 | 2007-11-22 | University Of Miami | Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma |
JP2010509244A (ja) * | 2006-11-13 | 2010-03-25 | エフ.ホフマン−ラ ロシュ アーゲー | 癌性疾患修飾抗体 |
CA2584494A1 (en) * | 2007-03-27 | 2008-09-27 | Jeffrey A. Medin | Vector encoding therapeutic polypeptide and safety elements to clear transduced cells |
WO2009114942A1 (en) * | 2008-03-20 | 2009-09-24 | University Health Network | Thymidylate kinase fusions and uses thereof |
EP2320941A2 (en) * | 2008-07-03 | 2011-05-18 | Duke University | Composition and methods for eliciting an immune response |
WO2013074793A1 (en) | 2011-11-15 | 2013-05-23 | University Of Miami | Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma |
JP6994021B2 (ja) * | 2016-08-26 | 2022-01-14 | ジュノー セラピューティクス インコーポレイテッド | 細胞組成物中に存在する粒子を計数する方法 |
CN110208056B (zh) * | 2019-06-06 | 2021-08-31 | 厦门大学附属第一医院 | 胃癌her-2 fish的组织芯片制作方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US657048A (en) * | 1899-11-23 | 1900-08-28 | Alfred M Acklin | Endless conveyer. |
US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
AU613590B2 (en) | 1986-11-19 | 1991-08-08 | Bristol-Myers Squibb Company | Hybridomas producing monoclonal antibodies to new mucin epitopes |
US4861581A (en) | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US5171665A (en) | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
DE4014510A1 (de) | 1990-05-07 | 1991-11-14 | Kernforschungsz Karlsruhe | Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie |
EP0539970B1 (en) | 1991-10-30 | 1999-05-26 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
IL105008A0 (en) | 1992-03-13 | 1993-07-08 | Yeda Res & Dev | Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis |
US5879898A (en) | 1992-11-20 | 1999-03-09 | Isis Innovation Limited | Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors |
WO1994012631A1 (en) * | 1992-11-20 | 1994-06-09 | Isis Innovation Limited | Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors |
CA2154266A1 (en) | 1993-02-05 | 1994-08-18 | John F. Codington | Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy |
EP0703989B1 (en) | 1993-06-18 | 1997-11-05 | Oy Biotie Therapies | COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6 |
UA58482C2 (uk) | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти |
EP0764030B1 (en) | 1994-06-24 | 2000-09-20 | Vladimir P. Torchilin | Composition containing autoantibodies for tumor therapy and prophylaxis |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
UY24389A1 (es) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | Composición farmacéutica para el tratamiento de carcinoma de epitelio plano |
AU6721696A (en) | 1996-07-15 | 1998-03-06 | Human Genome Sciences, Inc. | Cd44-like protein |
US6555652B1 (en) * | 1997-12-05 | 2003-04-29 | Kyogo Itoh | Tumor antigen peptide derivatives |
US6180357B1 (en) | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
US20040001789A1 (en) | 1999-10-08 | 2004-01-01 | Young David S. F. | Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof |
US6657048B2 (en) | 1999-10-08 | 2003-12-02 | Arius Research, Inc. | Individualized anti-cancer antibodies |
US7252821B2 (en) | 1999-10-08 | 2007-08-07 | Arius Research Inc. | Cancerous disease modifying antibodies |
US20030103985A1 (en) | 2001-05-18 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Cytotoxic CD44 antibody immunoconjugates |
MXPA03010523A (es) | 2001-05-18 | 2004-07-01 | Boehringer Ingelheim Pharma | Anticuerpos especificos para cd44v6. |
AU2002226211A1 (en) * | 2001-12-21 | 2003-07-15 | Arius Research, Inc. | Individualized anti-cancer antibodies |
-
2003
- 2003-08-22 US US10/647,818 patent/US7189397B2/en not_active Expired - Fee Related
-
2004
- 2004-08-20 ES ES04761710T patent/ES2379155T3/es not_active Expired - Lifetime
- 2004-08-20 EP EP04761710A patent/EP1667716B8/en not_active Expired - Lifetime
- 2004-08-20 CN CN201210172737.2A patent/CN102778562B/zh not_active Expired - Fee Related
- 2004-08-20 CN CN2004800314018A patent/CN1901936B/zh not_active Expired - Fee Related
- 2004-08-20 CA CA002536359A patent/CA2536359A1/en not_active Abandoned
- 2004-08-20 JP JP2006523500A patent/JP4981448B2/ja not_active Expired - Fee Related
- 2004-08-20 NZ NZ545477A patent/NZ545477A/en not_active IP Right Cessation
- 2004-08-20 AT AT04761710T patent/ATE538811T1/de active
- 2004-08-20 WO PCT/CA2004/001546 patent/WO2005018667A1/en active Application Filing
-
2011
- 2011-09-12 JP JP2011198848A patent/JP5468587B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-18 HK HK13103290.6A patent/HK1175846A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1667716B8 (en) | 2012-03-28 |
CN1901936A (zh) | 2007-01-24 |
EP1667716A4 (en) | 2007-05-16 |
ES2379155T3 (es) | 2012-04-23 |
CN102778562B (zh) | 2014-07-02 |
EP1667716A1 (en) | 2006-06-14 |
CN1901936B (zh) | 2012-08-08 |
JP2012031183A (ja) | 2012-02-16 |
EP1667716B1 (en) | 2011-12-28 |
ATE538811T1 (de) | 2012-01-15 |
CA2536359A1 (en) | 2005-03-03 |
NZ545477A (en) | 2009-09-25 |
JP5468587B2 (ja) | 2014-04-09 |
CN102778562A (zh) | 2012-11-14 |
JP4981448B2 (ja) | 2012-07-18 |
US20050008646A1 (en) | 2005-01-13 |
US7189397B2 (en) | 2007-03-13 |
JP2007503377A (ja) | 2007-02-22 |
WO2005018667A1 (en) | 2005-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1175846A1 (en) | Cytotoxicity mediation of cells evidencing surface expression of cd44 cd44 | |
EP1732602A4 (en) | CYTOTOXIC MEDIATION OF CELLS WITH SUPERFICIAL EXPRESSION OF MCSP | |
TW200731987A (en) | Cytotoxicity mediation of cells evidencing surface expression of CD44 | |
TW200637875A (en) | Cytotoxicity mediation of cells evidencing surface expression of CD63 | |
GB2449044A (en) | Cytotoxicity mediation of cells evidencing surface expression of cd63 | |
IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
WO2006012527A8 (en) | Bivalent linkers and conjugates thereof | |
UA85559C2 (xx) | Сполуки амінобензофенону$соединения аминобензофенона | |
WO2007016548A3 (en) | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer | |
EP2172476A3 (en) | Compositions and methods for WT1 specific immunotherapy | |
IL145535A0 (en) | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases | |
WO2002080754A3 (en) | Methods for using annexin for detecting cell death in vivo and treating associated conditions | |
MX2008008185A (es) | Antigenos de acido des-n-acetil-sialico, anticuerpos para los mismos, y metodos de uso en la terapia de cancer. | |
DE60206272D1 (de) | Chelatorkonjugate mit verbesserten eigenschaften | |
WO2008118733A3 (en) | Methods of treating cancer by administering human il-18 combinations | |
WO2009023955A8 (en) | Cytotoxicity mediation of cells evidencing surface expression of cd9 | |
WO2005065361A3 (en) | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | |
MX2009001014A (es) | Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie. | |
WO2002053700A3 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
HK1099026A1 (en) | Synthesis of spongosine | |
WO2003081250A8 (en) | Novel compositions and methods in cancer associated with altered expression of prlr | |
MX2009001642A (es) | Metodos para el tratamiento de leucemia de mieloide aguda. | |
WO2003079977A3 (en) | Novel compositions and methods in cancer associated with altered expression of mcm3ap | |
WO2003043565A3 (en) | Methods for diagnosis and treatment of diseases associated with altered expression of nrf2 | |
TH94953EX (th) | ชิ้นส่วนตัวเลื่อน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180820 |